The first small molecule-based tau PROTAC (QC-01-175) with evidence for efficacy in tauopathy patient iPSC-derived neuronal-based assays was developed in our group by optimally linking a minimal tau binding motive derived from T807 (Fig. 4a) and the small molecule pomalidomide (Fig. 4b), which recruits the CRL4CRBN E3 ligase complex (Fig. 3a) [101]. This evidence concerns the gene MAPT and tauopathy.